{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:10:10Z","timestamp":1755216610162,"version":"3.43.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>By analyzing the expression levels of circulating microRNAs (miRNAs) in patients with type 2 diabetes mellitus (T2DM) and its correlation with diabetic osteoporosis (DOP), this study aims to identify potential biomarkers for the early prediction and screening of DOP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 120 patients with T2DM who received treatment in the endocrinology outpatient\/inpatient department between January 2023 and June 2024, along with 90 healthy volunteers, were enrolled in this study. Based on the bone mineral density (BMD), the 120 T2DM patients were divided into three groups: normal group (54 cases), osteopenia group (38 cases), and osteoporosis group (28 cases). The differences in clinical data, laboratory test indicators and miRNA expression differences among the three groups were statistically analyzed, and the high-risk factors for DOP in T2DM patients were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to healthy volunteers, patients with T2DM demonstrated significantly decreased levels of P1NP and miR-219a-5p, alongside elevated levels of \u03b2-CTX, miR-188-3p, and miR-19a\/b. Additionally, miR-335-5p levels were notably reduced in T2DM patients. Among these markers, significant differences were observed in the expression levels of P1NP, \u03b2-CTX, and miRNA in T2DM patients. Further analysis revealed distinct expression patterns of miR-188-3p, miR-335-5p, and miR-19a\/b across the three T2DM subgroups (osteoporosis, osteopenia, and normal bone density groups). Specifically, miR-188-3p levels were 10.34 \u00b1 1.26 in the osteoporosis group, 8.35 \u00b1 1.33 in the osteopenia group, and 6.55 \u00b1 1.18 in the normal group. Similarly, miR-335-5p levels were 0.44 \u00b1 0.14, 0.67 \u00b1 0.16, and 0.88 \u00b1 0.15, respectively, while miR-19a\/b levels were 4.04 \u00b1 1.41, 3.19 \u00b1 1.21, and 2.47 \u00b1 1.24, respectively (P &amp;lt; 0.001 for all comparisons). These miRNAs also exhibited significant correlations with BMD at the hip and lumbar spine (P &amp;lt; 0.001 or P = 0.001), highlighting their potential role in bone metabolism and osteoporosis risk in T2DM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results suggest that the circulating levels of miR-188-3p, miR-335-5p, and miR-19a\/b are significantly associated with the occurrence of DOP in T2DM patients. These miRNAs show potential as biomarkers for the early diagnosis of DOP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1534725","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:59:50Z","timestamp":1754319590000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating microRNAs as a potential biomarker for osteoporosis in patients with type 2 diabetes mellitus: a retrospective clinical study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.22208","article-title":"Prevalence and treatment of diabetes in China, 2013-2018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-023-01049-4","article-title":"Diabetes and osteoporosis","volume":"57","author":"Prasad","year":"2023","journal-title":"Indian J Orthop"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.22-86","article-title":"Osteoporosis and diabetes: The dual pandemics","volume":"72","author":"Kalra","year":"2022","journal-title":"J Pak Med Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.03.006","article-title":"Diabetes and osteoporosis: part II, clinical management","volume":"50","author":"Schacter","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.03.005","article-title":"Diabetes and osteoporosis: part I, epidemiology and pathophysiology","volume":"50","author":"Schacter","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02806-x","article-title":"DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis","volume":"74","author":"Shevroja","year":"2021","journal-title":"Endocrine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101779","DOI":"10.1016\/j.berh.2022.101779","article-title":"Diabetes and osteoporosis - Treating two entities: A challenge or cause for concern","volume":"36","author":"Rasmussen","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137167","article-title":"MicroRNA-based diagnosis and therapy","volume":"23","author":"Ho","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2174\/1381612828666220128104206","article-title":"Potential effects of exosomes and their microRNA carrier on osteoporosis","volume":"28","author":"Li","year":"2022","journal-title":"Curr Pharm Des"},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40659-020-00309-z","article-title":"The roles of miRNA, lncRNA and circRNA in the development of osteoporosis","volume":"53","author":"Yang","year":"2020","journal-title":"Biol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00508-022-02122-y","article-title":"Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)","volume":"135","author":"Harreiter","year":"2023","journal-title":"Wien Klin Wochenschr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.19.03040-2","article-title":"Diabetes mellitus and osteoporosis","volume":"44","author":"Paschou","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.diff.2023.08.002","article-title":"The role of non-coding RNAs in diabetes-induced osteoporosis","volume":"133","author":"Wu","year":"2023","journal-title":"Differentiation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1618266","article-title":"An update on therapies for the treatment of diabetes-induced osteoporosis","volume":"19","author":"Mohsin","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.36290\/vnl.2021.076","article-title":"Osteoporosis in diabetes mellitus patients","volume":"67","author":"Jackuliak","year":"2021","journal-title":"Vnitr Lek"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094827","article-title":"Links among obesity, type 2 diabetes mellitus, and osteoporosis: bone as a target","volume":"25","author":"Martiniakova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.2174\/1573399816666200324152517","article-title":"Diabetes mellitus and osteoporosis correlation: challenges and hopes","volume":"16","author":"Ala","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-024-00867-1","article-title":"Diagnosing osteoporosis in diabetes-A systematic review on BMD and fractures","volume":"22","author":"Brandt","year":"2024","journal-title":"Curr Osteoporos Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00555-5","article-title":"Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus","volume":"17","author":"Khosla","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.554604","article-title":"Association of insulin resistance and beta-cell function with bone turnover biomarkers in dysglycemia patients","volume":"12","author":"Guo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.531904","article-title":"Correlation of osteoporosis in patients with newly diagnosed type 2 diabetes: A retrospective study in chinese population","volume":"12","author":"Wen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-06240-7","article-title":"The global approach to rehabilitation following an osteoporotic fragility fracture: A review of the rehabilitation working group of the International Osteoporosis Foundation (IOF) committee of scientific advisors","volume":"33","author":"Pinto","year":"2022","journal-title":"Osteoporos Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11914-022-00731-0","article-title":"MicroRNA and diabetic bone disease","volume":"20","author":"Daamouch","year":"2022","journal-title":"Curr Osteoporos Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00470","article-title":"hsa_circ_0026827 promotes osteoblast differentiation of human dental pulp stem cells through the beclin1 and RUNX1 signaling pathways by sponging miR-188-3p","volume":"8","author":"Ji","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2023.02.003","article-title":"MACF1 overexpression in BMSCs alleviates senile osteoporosis in mice through TCF4\/miR-335-5p signaling pathway","volume":"39","author":"Zhang","year":"2023","journal-title":"J Orthop Translat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13617","DOI":"10.15252\/emmm.202013617","article-title":"Antagonizing microRNA-19a\/b augments PTH anabolic action and restores bone mass in osteoporosis in mice","volume":"14","author":"Taipaleenmaki","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0772","article-title":"Effects of active acromegaly on bone mRNA and microRNA expression patterns","volume":"178","author":"Belaya","year":"2018","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1534725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:59:51Z","timestamp":1754319591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1534725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":29,"alternative-id":["10.3389\/fendo.2025.1534725"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1534725","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"article-number":"1534725"}}